Dronedarone for the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long odyssey?

This article refers to `Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial' by M. Vaduganathan et al., published in this issue on pages xxx.

Automated summary

This article discusses a post-hoc analysis of the ATHENA trial on the use of dronedarone for treating atrial fibrillation with concomitant heart failure. The findings suggest that dronedarone may have potential benefits in the treatment of this condition.